Rachael Liu

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Hodgkin Lymphoma

Electronic Health Record

Top Venues

Statistics in medicine

Journal of biopharmaceutical statistics

Leukemia & lymphoma

Pharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Wei Wei, Ondrej Blaha, Denise A Esserman, Daniel Zelterman, Michael J Kane, Rachael Liu, Jianchang Lin
A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics in medicine 43 (12) (2024)
Kai Chen, Yunqi Zhao, Meizi Liu, Jianchang Lin, Rachael Liu
DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior. Journal of biopharmaceutical statistics (2024)
Wei Wei, Ondrej Blaha, Denise A Esserman, Daniel Zelterman, Michael J Kane, Rachael Liu, Jianchang Lin
A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics in medicine (2024)
Wei Wei, Ondrej Blaha, Denise A Esserman, Daniel Zelterman, Michael J Kane, Rachael Liu, Jianchang Lin
A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics in medicine 43 (12) (2024)
Wei Wei, Ondrej Blaha, Denise A Esserman, Daniel Zelterman, Michael J Kane, Rachael Liu, Jianchang Lin
A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics in medicine 43 (12) (2024)
Dehua Bi, Meizi Liu, Jianchang Lin, Rachael Liu
BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints. Statistics in medicine (2023)
Yunqi Zhao, Rachael Liu, Kentaro Takeda
Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET. Pharmaceutical statistics (2022)
Tian He, Rachael Liu, Meizi Liu, Jianchang Lin
PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints. Journal of biopharmaceutical statistics 32 (4) (2022)
Martin Hutchings, John Radford, Stephen M Ansell, Árpád Illés, Anna Sureda, Joseph M Connors, Alice Sýkorová, Hirohiko Shibayama, Jeremy S Abramson, Neil S Chua, Jonathan W Friedberg, Jan Kořen, Ann Steward LaCasce, Lysiane Molina, Gerald Engley, Keenan Fenton, Hina Jolin, Rachael Liu, Ashish Gautam, Andrea Gallamini
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematological oncology 39 (2) (2021)
Pin Li, Rachael Liu, Jianchang Lin, Yuan Ji
TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy. Journal of biopharmaceutical statistics 30 (6) (2020)
Mo Li, Rachael Liu, Jianchang Lin, Veronica Bunn, Hongyu Zhao
Bayesian Semi-parametric Design (BSD) for adaptive dose-finding with multiple strata. Journal of biopharmaceutical statistics 30 (5) (2020)
David Straus, Graham Collins, Jan Walewski, Pier Luigi Zinzani, Andrew Grigg, Anna Sureda, Arpad Illes, Tae Min Kim, Sergey Alekseev, Lena Specht, Valeria Buccheri, Anas Younes, Joseph Connors, Andres Forero-Torres, Keenan Fenton, Ashish Gautam, Indra Purevjal, Rachael Liu, Andrea Gallamini
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leukemia & lymphoma 61 (12) (2020)